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1. Introduction 
A 74-year old man with complaints of malaise was diagnosed with acute renal failure of 
unknown cause and was referred to our outpatient clinic because of bluish-red maculae in a 
reticular pattern on his forefeet and toes of unclear duration. Six weeks prior to the onset  
of his general symptoms he had undergone an endovascular aorta repair (EVAR) procedure. 
A lesional skin biopsy was taken and revealed multiple cholesterol emboli. The cholesterol 
emboli syndrome is a complication of atherosclerosis caused by cholesterol crystal 
embolization. These cholesterol crystals originate from atherosclerotic plaques of the  
large arteries and can migrate to various organs like the kidneys and the skin where they 
occlude small arteries causing ischemia and tissue damage. Often precipitating factors  
like vascular procedures, cardiac or aorta surgery, or treatment with anticoagulant  
or thrombolytic drugs can be identified. With our cutaneous findings an invasive renal 
biopsy could be avoided. 
2. Case 
A 74-year old man was referred to our Dermatology outpatient clinic by a nephrologist 
because of non-painful bluish-red discoloration of his feet and toes of unclear duration. He 
had been suffering from general malaise for some days and the laboratory results in the 
emergency department had revealed acute renal insufficiency of unknown cause. Six weeks 
prior to the emergence of symptoms he was treated for an aneurysm of the infrarenal aorta 
with a so-called EVAR (Endovascular Aneurysm Repair or Endovascular Aortic Repair) 
procedure.  
On physical examination we observed livid-erythematous maculae in a reticular pattern  
on the distal end of both feet and toes (figure 1). The pulsations of the tibialis posterior  
and dorsalis pedis arteries were present, and there was a normal capillary refill.  
Laboratory results showed a creatinine of 601 µmol/L, urea of 359 mmol/L, an erythrocyte 
sedimentation rate (ESR) of 70 mm/hour, a white blood cell (WBC) count of 8.4 x109/L, with 
eosinophils of 0.59x109/L, and thrombocytes of 161x109/L. 
We performed a 3 mm lesional skin biopsy (from a blanched area) which showed compact 
hyperkeratosis and a normally structured epidermis and dermis. However, in the dermis we 
observed a small artery with some intimal hyperplasia containing a number of needle-shaped  
www.intechopen.com







Fig. 1. Livid-erythematous maculae in a reticular pattern on the plantar surface of the distal 
forefoot and toes. 
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spaces which occluded the lumen (figure 2). Herewith a histological diagnosis of cholesterol 
emboli syndrome was made. 
3. Discussion 
The cholesterol emboli syndrome (or cholesterol embolization syndrome) is a 
complication of atherosclerosis as a result of cholesterol crystal embolization. These 
cholesterol crystals originate from atherosclerotic  plaques in the larger arteries and  
can migrate to various organs like the skin, the kidneys, gastro-intestinal system and 
central nervous system. Because these small crystals are hydrophobic and low in weight 
they can travel swiftly through the blood vessels until they strand in the arterial 
bifurcations or when the calibre of the arterial lumen decreases. This means that they  
will usually occlude small peripheral arteries leading to localized ischaemia which can 
result in (sometimes severe) end-organ damage. The cholesterol emboli syndrome 
primarily affects patients above 60 years of age with two or more risk factors for 
atherosclerosis.(1, 2)  
The incidence of the syndrome in the general population, is low. For example, in the Dutch 
population, an average rate of 6.2 cases per million people per year has been reported.(3) 
However, in high risk patients, such as those undergoing cardiac catheterization, incidence 
rates up to 1.4% have been reported.(4) 
In post-mortem studies, cholesterol emboli were observed in up to 20% of patients older 
than 60 years of age with a history of atherosclerotic disease.(5) Considering the relatively 
low rate of the clinical diagnosis of cholesterol emboli (even in high risk patients groups), it 
thus appears  that the diagnosis  is  frequently missed.  
Since the disintegration of (ulcerated) atherosclerotic plaques in the arterial vessel wall is 
the cause of cholesterol embolization, affected patients generally have severe (but 
sometimes subclinical) atherosclerotic disease. Although the syndrome may appear 
spontaneously without any clearly established predisposing etiological factor, there are 
three distinctive clinical settings that are known to increase the risk for cholesterol 
embolization. The first is prior arterial or coronary catheterisation (as for our patient) and 
cardiac or aorta surgery, which may disrupt an atherosclerotic plaque, leading to emboli 
within hours to several weeks of the procedure. The second is prolonged treatment with 
anticoagulant drugs, which slowly dissolves the clot that strengthens the brittle 
atherosclerotic plaque exposing eroded areas of the plaque to the shear stress of the 
arterial blood flow. The anticoagulant drug-induced syndrome of cholesterol emboli 
usually occurs within 1 to 2 months of initiating therapy. This ‘warfarin blue toe 
syndrome’ is not limited to anticoagulation with warfarin and can occur after treatment 
with other (classes of) anticoagulant drugs. The third setting in which cholesterol 
embolization can occur is when thrombolytic therapy is initiated for acute myocardial 
infarction or stroke. In this case, the embolization process may occur within hours to days 
of thrombolytic therapy.(6)  A summary of the most common predisposing factors for 
cholesterol emboli syndrome is presented in table 1.(1, 7-10)  
In our case the referring nephrologist made a provisional diagnosis of acute renal 
insufficiency due to cholesterol embolization related to the prior EVAR procedure after 
excluding all other possible causes. When performing an EVAR procedure of the  
infra-renal aorta, the catheters usually reach above the renal artery branches. 
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Manipulation with the endovascular catheter and stent in this area can cause small 
fragments (emboli) to detach from a friable atherosclerotic plaque in the arterial wall.  
The nephrologist sought support for his provisional diagnosis in the accompanying  
skin symptoms since the emboli can also migrate to the peripheral small arteries in the  
skin resulting in the typical reticular vascular pattern. With the demonstration of 
cholesterol emboli in a skin biopsy a more invasive ('gold standard') renal biopsy could  
be avoided. 
In the cholesterol emboli syndrome the clinical symptoms may include fever, weight loss, 
myalgias, altered mental status and a rapid onset of arterial hypertension. Transient 
ischemic attacks, strokes, renal failure, gastrointestinal ulcerations and hemorrhagic 
pancreatitis may also occur. Patients with extensive organ involvement can have 
significant morbidity, and may even die from complications of the embolization 
process.(6) Generally, the primary site of cholesterol embolization is the kidney, followed 
by the skin and gastrointestinal tract.(3) Skin manifestations are present in 35 to 100% of 
patients and are often the first clinical symptom of the cholesterol emboli syndrome. Their 
clinical presentation is variable ranging from the symmetrical livedo reticularis, 
acrocyanosis, ulcerations, and purpura to severe leg and/or foot pain and focal digital 
ischaemia ("blue toe syndrome")(11).  Findings of a relatively large English case study 
included: livedo reticularis (49%), multiple sites of peripheral gangrene (35%), cyanosis 
(28%), ulceration (17%), nodules (10%) and (retiform) purpura (9%).(5) Because these 
figures originate from a review article that also included patients in whom the diagnosis 
was made post-mortem (41%), it probably underestimated the true incidence of cutaneous 
findings in patients suffering from the cholesterol emboli syndrome.(6) This point is 
corroborated by a study of eight patients with acute renal insufficiency of unknown cause, 
whose history suggested cholesterol emboli. On careful examination, all eight were  
found to have prior unrecognized  livedo reticularis, which on histological sections 
confirmed the diagnosis of cholesterol emboli.(12) In two of these patients, the livedo 
reticularis was visible in the standing position, but disappeared when the patients were 
placed in the supine position. Retiform purpura are usually a purpuric accentuation of  
the livedo reticularis pattern, and therefore may have been included as livedo reticularis 
in some reports. This may explain the relatively low observation rate of retiform purpura 
in the study by Falanga et al. Livedo reticularis is ususally found in the lower extremities 
but upper extremity lesions may also occur if the atherosclerotic plaque is located in the 
aortic arch.(6) 
The skin manifestations are often (but not always) painful and peripheral pulsations are 
generally intact.  Elevations in the ESR, serum creatinine, BUN and amylase and transient 
elevations of creatine kinase, leukocytosis, thrombocytopenia as well as  decreased 
complement levels are frequent associated findings, but are not always present.(5, 13) 
Peripheral blood eosinophilia is common, occurring in up to 80% of confirmed cases, and 
may be related to generation of the complement component C5.(13) Other reported 
laboratory findings include heme-positive urine and/or stool. 
The acute onset of peripheral livedo reticularis (and even more so if retiform purpura are 
also present) should raise the suspicion of cholesterol or oxalate embolization. The 
occurrence of oxalate emboli is rare and recognized histologically as birefringent yellow-
brown crystal depositions in and around arteries of deep reticular dermis and subcutis. 
Oxalate crystal embolization is an uncommon event, usually occurring in association with 
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primary hyperoxaluria. Primary hyperoxaluria is caused by a rare metabolic disorders of 
increased oxalic acid production or increased intestinal absorption. Hyperoxalemia will 
eventually lead to calcium oxalate deposition in various tissues.(14, 15) The history of 
kidney stones in a patient with sudden-onset livedo reticularis or retiform purpura should 
point in the direction of hyperoxaluria as a key diagnostic possibility. In addition to emboli 
from acute bacterial or fungal endocarditis (which are generally inflammatory in nature), 
cutaneous emboli or thrombi have been occasionally reported in patients with atrial 
myxomas, marantic endocarditis, crystal globulins and hypereosinophilic syndrome. Emboli 
resulting from these disorders may produce retiform purpura, but cutaneous manifestations 
may vary.(6) Other differential diagnoses one should consider include (small vessel) 
vasculitis (kidney and skin involvement) and perniones ("chilblains").(16) 
A lesional (large) skin biopsy or elliptical excision of a blanched area of the livedo 
reticularis is diagnostic in 92% of cases, provided the sample includes tissue from the 
mid- to deep reticular dermis.(1) Areas of retiform purpura usually provide excellent 
diagnostic findings in punch biopsy specimens and should be the first choice for biopsy 
when present.(6) Frozen sections show birefringent cholesterol crystals and with  
the Schulz staining blue-green coloured crystals can be observed.(17) However, in fixated 
material the cholesterol crystals are dissolved during the laboratory workup and  
the negative image remains in the form of needle-shaped optical empty spaces  
(figure 2), often in association with thrombi.(18) Neutrophils, eosinophils and 
mononuclear cells may be present in the arterial wall within 24-48 hours in an 
experimentally produced cholesterol embolus. This is followed by the invasion of 
multinucleated histiocytes within 3 to 6 days, and sometimes intimal fibrosis. Lesions of 
different ages can be observed in the same patient, which is consistent with repeated 
showers of emboli.(6) 
The cholesterol emboli syndrome is associated with a very high mortality rate (up to 
80%).(1, 2) The prognosis depends on the degree of organ damage and severity of the 
underlying vascular condition. Treatment with aspirin appears to have a beneficial effect 
and in patients suffering from aortal atherosclerosis regression of the atherosclerotic plaque 
size was observed upon treatment with statins.(19) Furthermore, discontinuation of 
anticoagulation, initiation of anticoagulation in patients with severe renal damage, 
corticosteroid therapy, and infusion of the prostacyclin analogue iloprost have all been 
proposed as being effective in sporadic patients, but no therapeutic gold standard exists.(13, 
18, 20) Additional measures include supportive treatment like hydration, antihypertensive 
therapy and haemodialysis.(21) Our patient needed long term haemodialysis; after 
approximately one and half year spontaneous recovery of renal function occurred, allowing 
discontinuation of haemodialysis.  
4. Conclusion 
In summary, we believe that in all patients presenting with the classical triad of peripheral 
livedo reticularis, acute renal failure, and eosinophilia, the cholesterol emboli syndrome 
should be suspected. An invasive vascular procedure or recent initiation of anticoagulant or 
thrombolytic treatment in the months preceding onset of symptoms is an important 
diagnostic clue. A proper (large) lesional skin biopsy can confirm the diagnosis and 
therewith a more invasive renal biopsy can be avoided.  
www.intechopen.com




Fig. 2. Histological slide showing a small dermal artery branch with needle-shaped optical 
empty spaces as a result of the cholesterol crystals that dissolved during tissue  processing 
(HE 20x). 
 
The cholesterol emboli syndrome should be suspected if the following items apply:  
• confirmed atherosclerotic lesions in large vessels 
• history of potential triggering predisposing factors (see below) 
• typical clinical presentation, including renal failure, livedo reticularis or ulceration of 
the toes with intact peripheral arterial pulsations 
• exclusion of small vessel vasculitis 
• exclusion of diseases causing infective emboli (e.g. endocarditis) 
• typical histopathological findings; evidence of cholesterol crystals (optical empty 
spaces) in the lumen of small arteries accompanied by an inflammatory cell infiltrate 
 
Potential predisposing factors for the cholesterol emboli syndrome: 
• angioplasty 
• vascular surgery 
• any invasive vascular procedure (including angiography) 
• prolonged anticoagulant therapy 
• fibrinolytic therapy 
Table 1. Diagnosis of the cholesterol emboli syndrome  
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